DK1452528T3 - Xanthinoxidaserinhibitorer - Google Patents

Xanthinoxidaserinhibitorer

Info

Publication number
DK1452528T3
DK1452528T3 DK02780099T DK02780099T DK1452528T3 DK 1452528 T3 DK1452528 T3 DK 1452528T3 DK 02780099 T DK02780099 T DK 02780099T DK 02780099 T DK02780099 T DK 02780099T DK 1452528 T3 DK1452528 T3 DK 1452528T3
Authority
DK
Denmark
Prior art keywords
xanthine oxidase
oxidase inhibitors
substituent
carboxyl
halogen
Prior art date
Application number
DK02780099T
Other languages
Danish (da)
English (en)
Inventor
Shinichi Yoshida
Atsushi Tendo
Kunio Kobayashi
Nobutaka Mochiduki
Tomio Yamakawa
Yoriko Shinohara
Original Assignee
Nippon Chemiphar Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Chemiphar Co filed Critical Nippon Chemiphar Co
Application granted granted Critical
Publication of DK1452528T3 publication Critical patent/DK1452528T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK02780099T 2001-11-16 2002-11-14 Xanthinoxidaserinhibitorer DK1452528T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001352340 2001-11-16
PCT/JP2002/011893 WO2003042185A1 (fr) 2001-11-16 2002-11-14 Inhibiteurs de la xanthine oxydase

Publications (1)

Publication Number Publication Date
DK1452528T3 true DK1452528T3 (da) 2008-11-10

Family

ID=19164532

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02780099T DK1452528T3 (da) 2001-11-16 2002-11-14 Xanthinoxidaserinhibitorer

Country Status (11)

Country Link
US (2) US7253154B2 (ja)
EP (1) EP1452528B1 (ja)
JP (2) JP4634037B2 (ja)
KR (1) KR100919147B1 (ja)
CN (2) CN101092400A (ja)
AT (1) ATE404541T1 (ja)
DE (1) DE60228316D1 (ja)
DK (1) DK1452528T3 (ja)
ES (1) ES2309213T3 (ja)
PT (1) PT1452528E (ja)
WO (1) WO2003042185A1 (ja)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2510455C (en) 2002-12-19 2013-03-12 The Scripps Research Institute Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
CA2565037A1 (en) * 2004-04-28 2005-11-10 Cv Therapeutics, Inc. Purine derivatives as a1 adenosine receptor antagonists
KR101191071B1 (ko) 2004-06-14 2012-10-15 닛뽕 케미파 가부시키가이샤 축합 피리미딘 유도체 및 크산틴 옥시다제 저해제
US7598254B2 (en) * 2004-06-14 2009-10-06 Nippon Chemiphar Co., Ltd. Substituted 1,3-thiazolo[5,4-d]pyrimidines as xanthine oxidase inhibitors
JP2008506785A (ja) * 2004-07-21 2008-03-06 フロリダ大学 リサーチファウンデーション インコーポレイティッド インスリン抵抗性の治療及び予防のための組成物及び方法
JPWO2007004688A1 (ja) * 2005-07-01 2009-01-29 日本ケミファ株式会社 キサンチンオキシダーゼ阻害剤
KR20140037954A (ko) * 2006-06-22 2014-03-27 닛뽕 케미파 가부시키가이샤 항암제 내성 극복제
WO2008034016A2 (en) * 2006-09-15 2008-03-20 Foldrx Pharmaceuticals, Inc. Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins
WO2008126899A1 (ja) * 2007-04-11 2008-10-23 Kissei Pharmaceutical Co., Ltd. ５員環へテロ環誘導体及びその医薬用途
EP2165705A1 (en) 2008-09-18 2010-03-24 Centre National de la Recherche Scientifique (CNRS) Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis
JP5673008B2 (ja) 2010-08-11 2015-02-18 ソニー株式会社 画像処理装置、立体画像表示装置および立体画像表示システム、ならびに立体画像表示装置の視差ずれ検出方法および立体画像表示装置の製造方法
CN102095825B (zh) * 2010-12-08 2014-07-23 中国科学院长春应用化学研究所 超高效液相色谱和质谱联用筛选黄嘌呤氧化酶抑制剂的方法
WO2013038351A1 (en) 2011-09-16 2013-03-21 Pfizer Inc. Solid forms of a transthyretin dissociation inhibitor
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
WO2014151630A2 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
HUE040254T2 (hu) 2013-12-19 2019-02-28 Novartis Ag Protozoa proteaszóma inhibitor [1,2,4]triazolo[1,5-a]pirimidinszármazékok paraziták által okozott betegségek, például leishmaniasis kezelésére
JP2017048116A (ja) * 2014-01-10 2017-03-09 国立研究開発法人国立国際医療研究センター 肺高血圧症治療薬
JP6891108B2 (ja) * 2015-02-24 2021-06-18 国立大学法人鳥取大学 認知症の予防及び／又は治療のための医薬
CN106146533B (zh) * 2016-07-14 2018-04-03 华润赛科药业有限责任公司 含硫杂环羧酸类衍生物、其制备方法和应用
WO2020009374A1 (ko) * 2018-07-04 2020-01-09 고려대학교 세종산학협력단 4-치환 옥사졸로퀴놀리논 유도체, 약학적으로 허용되는 이의 염인 화합물 및 이를 유효성분으로 포함하는 천식 또는 아토피 등의 알러지성 질환의 예방 또는 치료용 약학 조성물
CN110283137A (zh) * 2019-06-13 2019-09-27 爱斯特（成都）生物制药股份有限公司 一种2-(4-溴苯基)-1,3-苯并恶唑的制备方法
CN111620833A (zh) * 2020-06-05 2020-09-04 青岛伯川特聚科技有限公司 一种2-苯基苯并噁唑类化合物的制备方法
CN113004188B (zh) * 2021-03-16 2022-09-20 沈阳药科大学 一种吲哚衍生物及制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4038396A (en) * 1975-02-24 1977-07-26 Merck & Co., Inc. Anti-inflammatory oxazole[4,5-b]pyridines
DE2927988A1 (de) * 1979-07-11 1981-02-05 Thomae Gmbh Dr K Neue 8-phenyl-purine, deren herstellung und deren verwendung als arzneimittel
RO86850B (ro) 1982-05-03 1985-05-31 Eli Lilly And Company Procedeu pentru prepararea unor 2-fenilimidazo [4,5 c] piridine
JPS62246581A (ja) * 1986-04-17 1987-10-27 Chugai Pharmaceut Co Ltd フロベンゾオキサゾ−ル誘導体
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
JPH03258770A (ja) 1990-03-08 1991-11-19 Tanabe Seiyaku Co Ltd ベンズアゾール誘導体、その製法及びその合成中間体
JP3176073B2 (ja) * 1990-06-19 2001-06-11 キヤノン株式会社 液晶素子
AU2001259707A1 (en) * 2000-06-14 2001-12-24 Warner Lambert Company 6,5-fused bicyclic heterocycles
EP1294686A2 (en) 2000-06-14 2003-03-26 Warner-Lambert Company Indole derivatives and their use as 15-lipoxygenase inhibitors
GB0205256D0 (en) 2002-03-06 2002-04-17 Oxford Glycosciences Uk Ltd Novel compounds

Also Published As

Publication number Publication date
CN100338040C (zh) 2007-09-19
US20070265283A1 (en) 2007-11-15
JP2010180232A (ja) 2010-08-19
JP5297414B2 (ja) 2013-09-25
EP1452528B1 (en) 2008-08-13
DE60228316D1 (en) 2008-09-25
JP4634037B2 (ja) 2011-02-16
EP1452528A1 (en) 2004-09-01
JPWO2003042185A1 (ja) 2005-03-10
ES2309213T3 (es) 2008-12-16
KR20040065223A (ko) 2004-07-21
ATE404541T1 (de) 2008-08-15
WO2003042185A1 (fr) 2003-05-22
US20050090472A1 (en) 2005-04-28
CN101092400A (zh) 2007-12-26
EP1452528A4 (en) 2005-11-16
PT1452528E (pt) 2008-10-14
CN1615299A (zh) 2005-05-11
KR100919147B1 (ko) 2009-09-25
US7253154B2 (en) 2007-08-07

Similar Documents

Publication Publication Date Title
ATE404541T1 (de) Xanthinoxidaseinhibitoren
ATE512154T1 (de) Kondensiertes pyrimidinderivat und xanthinoxidaseinhibitor
NZ505968A (en) Sulfonylamino derivatives which inhibit matrix- degrading metallproteinases
ATE345122T1 (de) Stabile emulsionszubereitungen
EA200100755A1 (ru) 4-оксо-1,4-дигидро-3-хинолинкарбоксамиды как антивирусные агенты
CA2432713A1 (en) Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
EA199900591A1 (ru) АЗОТСОДЕРЖАЩИЕ ГЕТЕРОАРОМАТИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Ха
DK0787726T3 (da) Ny forbindelse, fremgangsmåde til fremstilling deraf og antitumor-middel
AU2003246100A1 (en) Amide derivative
DE69332792D1 (de) 4,1-Benzoxazepinderivate als Squalen-Synthetase Inhibitoren und ihre Verwendung zur Behandlung von Hypercholesterämie und als Fungizide
NO20004485D0 (no) Sykloalkenderivater, deres fremstilling og anvendelse
DK0790987T3 (da) Aminotetrazol-derivater, der er anvendelige som nitrogenoxidsynthaseinhibitorer
EP1666469A4 (en) INHIBITOR OF INHIBITOR-1 PLASMOGENIC ACTIVATOR
EA200000614A1 (ru) 2,3-замещенные соединения индола в качестве ингибиторов сох-2
DE69722858D1 (de) Intimale verdickungsinhibitoren
DK0618193T3 (da) Nitrogenholdige, bicycliske derivater som prolyl-endopeptidaseinhibitorer
HUP0302193A2 (hu) 1,4-Diazabiciklo[3.2.2]nonán-benzoxazol,-benzotiazol és -benzimidazol-származékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények
WO2003068744A1 (fr) Derives de la pyridine ou leurs sels, et inhibiteurs de production de citokine renfermant ces derives
ATE445619T1 (de) Pyridinylpyrazolopyrimidinon-derivate als pde 7 inhibitoren
ATE201402T1 (de) Optisch aktive thiazolidinonderivate
ATE440100T1 (de) Prenyl transferasinhibitoren
DE60239324D1 (de) Phenyl- und pyridyl-piperidine mit tnf-wirkung